N/A N=101 ABSORB Clinical Investigation, Cohort B
Coronary Disease · Coronary Artery Disease · Coronary Restenosis
Primary: Hierarchical Major Adverse Cardiac Event (MACE) — 2.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=468 Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
Asthma
Primary: Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment — 0.52; 0.41 events — p=0.194
Phase 1 N=40 Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
Ebola Virus Disease
Primary: Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse…
Phase 2 N=53 Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.
Renal Impairment
Primary: Change From Baseline in 24-hour Urinary Glucose Excretion (UGE) on Day 7 — 40.45; 31.87; 36.27; 19.88 gram (g) — p=0.154
N/A N=52 Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
Methamphetamine Abuse · HIV
Primary: Discounting Tasks: Sexual Probability Discounting (SexPD) — 2.97; 6.52; 4.68; 7.67 natural log
N/A N=21 Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
Pelvic Pain
Primary: Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS). — -2; -1 units on a scale — p=0.072
Phase 4 N=24 Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine
Anesthesia, Local
Primary: Mean Time to Pulpal Response After Mandibular Molar Anesthesia — 100; 106 minutes
Phase 2 N=9 Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 77.8 Percentage of participants
Phase 3 N=2,123 A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
Asthma
Primary: Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients — -0.005; -0.005; -0.007; -0.005 10^9 cells/L
Phase 2 N=36 Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study — 3; 2; 7; 4 Participants
Phase 2 N=121 A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Number of Participants With Adverse Events (AEs) — 0; 0; 0; 0 Participants
N/A N=13 Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management
Sickle Cell Disease
Primary: System Usability Questionnaire — 86.67 units on a scale
Phase 2 N=312 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Number and Percentage of Subjects Who Achieved a Response at Week 24 According to the Modified British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus…
Phase 2 N=36 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
T-cell Acute Lymphoblastic Leukemia · T-cell Lymphoblastic Lymphoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 2; 2; 3 Participants
N/A N=450 Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Septic Shock · Endotoxemia
Primary: Mortality — 78; 84 Participants